201 related articles for article (PubMed ID: 20930099)
1. Hepatitis B reactivation and rituximab in the oncology practice.
Villadolid J; Laplant KD; Markham MJ; Nelson DR; George TJ
Oncologist; 2010; 15(10):1113-21. PubMed ID: 20930099
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma.
Cho CH; Hwang WL; Cheng SB; Lee TY; Teng CL
Ann Hematol; 2011 Jan; 90(1):111-2. PubMed ID: 20407894
[No Abstract] [Full Text] [Related]
3. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
4. Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance.
Chew E; Thursky K; Seymour JF
Leuk Lymphoma; 2014 Apr; 55(4):938-9. PubMed ID: 23772645
[No Abstract] [Full Text] [Related]
5. Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation.
Martin ST; Cardwell SM; Nailor MD; Gabardi S
Am J Transplant; 2014 Apr; 14(4):788-96. PubMed ID: 24592928
[TBL] [Abstract][Full Text] [Related]
6. A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience.
Oh MJ; Lee HJ
Clin Mol Hepatol; 2013 Mar; 19(1):51-9. PubMed ID: 23593610
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge.
Thompson PA; Tam CS; Thursky K; Seymour JF
Leuk Lymphoma; 2010 Sep; 51(9):1592-5. PubMed ID: 20807092
[No Abstract] [Full Text] [Related]
8. An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening.
Leung C; Tsoi E; Burns G; Sievert W
Oncologist; 2011; 16(5):579-84. PubMed ID: 21464465
[TBL] [Abstract][Full Text] [Related]
9. Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation.
Liu CY; Chandrasekar PH; Masood A; Schiffer CA
J Oncol Pharm Pract; 2013 Mar; 19(1):18-23. PubMed ID: 22635416
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
[TBL] [Abstract][Full Text] [Related]
12. Is antiviral prophylaxis necessary to prevent hepatitis B virus (HBV) reactivation in patients with HBV-resolved infection receiving rituximab-containing chemotherapy?
Kusumoto S; Tanaka Y; Mizokami M; Ueda R
J Clin Oncol; 2013 Dec; 31(35):4480. PubMed ID: 24220561
[No Abstract] [Full Text] [Related]
13. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.
Liu WP; Zheng W; Song YQ; Ping LY; Wang GQ; Zhu J
World J Gastroenterol; 2014 May; 20(17):5165-70. PubMed ID: 24803836
[TBL] [Abstract][Full Text] [Related]
14. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.
Kusumoto S; Tanaka Y; Ueda R; Mizokami M
J Gastroenterol; 2011 Jan; 46(1):9-16. PubMed ID: 20924616
[TBL] [Abstract][Full Text] [Related]
16. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab.
Zell JA; Yoon EJ; Ignatius Ou SH; Hoefs JC; Chang JC
Anticancer Drugs; 2005 Jan; 16(1):83-5. PubMed ID: 15613909
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus reactivation in a patient with resolved hepatitis B virus infection receiving maintenance rituximab for malignant B-cell lymphoma.
Koo YX; Tan DS; Tan IB; Tao M; Lim ST
Ann Intern Med; 2009 May; 150(9):655-6. PubMed ID: 19414854
[No Abstract] [Full Text] [Related]
18. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports.
Evens AM; Jovanovic BD; Su YC; Raisch DW; Ganger D; Belknap SM; Dai MS; Chiu BC; Fintel B; Cheng Y; Chuang SS; Lee MY; Chen TY; Lin SF; Kuo CY
Ann Oncol; 2011 May; 22(5):1170-1180. PubMed ID: 21115603
[TBL] [Abstract][Full Text] [Related]
19. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
20. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb.
Sarrecchia C; Cappelli A; Aiello P
J Infect Chemother; 2005 Aug; 11(4):189-91. PubMed ID: 16133710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
